CITIUS ONCOLOGY INC

Historical 13F Holders

Reported Value, Excluding Options

Total Filings

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 17331Y109 since 12/18/2024, largest first.

Filer	% of Class	Shares	Form	Filed
Citius Pharmaceuticals, Inc. 13D/A	71.0%	66,049,615	13D/A	6/4/2026 Event 5/15/2026
Armistice Capital, LLC 13G/A	10.0%	9,353,553	13G/A	8/14/2026 Event 6/30/2026
Armistice Capital, LLC	10.0%	9,353,553
Steven Boyd	10.0%	9,353,553

Period	Filings	Shares, Excl. Options	Value, Excl. Options	Options Value
2026 Q2	19	14.1 M	$9.20 M	$0
2026 Q1	14	14.2 M	$8.83 M	$0
2025 Q4	18	6.86 M	$6.86 M	$0
2025 Q3	16	8.36 M	$17.0 M	$0
2025 Q2	8	227 k	$990 k	$0
2025 Q1	7	105 k	$97.7 k	$0
2024 Q4	12	201 k	$230 k	$0
2024 Q3	8	41.2 k	$57.0 k	$0